Lung transplantation for pulmonary hypertension

Pulmonary Circulation

Volumn 1, Issue 2, 2011, Pages 182-191

  George, M Patricia ^a   Champion, Hunter C ^a   Pilewski, Joseph M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Lung transplant; Outcome; Pulmonary arterial hypertension; Surgical treatment

Indexed keywords

EID: 84859024667     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.83455     Document Type: Review

References (73)

1. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med 1951;11:686-705.
2. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
3. Reitz BA. The first successful combined heart-lung transplantation. J Thorac Cardiovasc Surg 2011;141:867-9.
4. Cooper JD, Pearson FG, Patterson GA, Todd TR, Ginsberg RJ, Goldberg M, et al. Technique of successful lung transplantation in humans. J Thorac Cardiovasc Surg 1987;93:173-81
5. Patterson GA, Cooper JD, Goldman B, Weisel RD, Pearson FG, Waters PF, et al. Technique of successful clinical double-lung transplantation. Ann Thorac Surg 1988;45:626-33
6. Kaiser LR, Pasque MK, Trulock EP, Low DE, Dresler CM, Cooper JD. Bilateral sequential lung transplantation: The procedure of choice for double-lung replacement. Ann Thorac Surg 1991;52:438-45; discussion 445-6.
7. Christie JD, Edwards LB, Kucheryavaya AY, Aurora P, Dobbels F, Kirk R, et al. The registry of the International Society for Heart and Lung Transplantation: Twenty-seventh official adult lung and heart-lung transplant report--2010. J Heart Lung Transplant 2010;29:1104-18
8. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982;66:334-8.
9. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046-7.
10. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485-91.
11. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996;334:296-302.
12. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
13. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
14. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-70.
15. Machherndl S, Kneussl M, Baumgartner H, Schneider B, Petkov V, Schenk P, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J 2001;17:8-13.
16. Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, Seyfarth HJ. Inhaled iloprost for the control of pulmonary hypertension. Vasc Health Risk Manag 2009;5:465-74.
17. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
18. Jacobs A, Preston IR, Gomberg-Maitland M. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ETA inhibition? Curr Med Res Opin 2006;22:2567-74.
19. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
20. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21.
21. Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M, et al. Discovery of riociguat (BAY 63-2521): A potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009;4:853-65.
22. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of ran domized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
23. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association. J Am Coll Cardiol 2009;53:1573-619.
24. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54.
25. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
26. Forfia PR, Mathai SC, Fisher MR, Housten-Harris T, Hemnes AR, Champion HC, et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;177:1364-9.
27. Takeda Y, Takeda Y, Tomimoto S, Tani T, Narita H, Kimura G. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. BMC Pulm Med 2010;10:22.
28. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006;174:1034-41.
29. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92.
30. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from reveal: Identifying systemic sclerosis as a unique phenotype. Chest 2010;138:1383-94.
31. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in copd: Epidemiology, significance, and management: Pulmonary vascular disease: The global perspective. Chest 2010;137:39S-51S.
32. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995;107:1193-8.
33. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-94.
34. Weitzenblum E, Chaouat A, Canuet M, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med 2009;30:458-70.
35. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746-52.
36. Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, Nagao T, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007;131:650-6.
37. Palmero V, Sulica R. Sarcoidosis-associated pulmonary hypertension: Assessment and management. Semin Respir Crit Care Med 2010;31:494-500.
38. Heresi GA, Dweik RA. Sarcoidosis-associated pulmonary hypertension. One size does not fit all. Chest 2009;135:1410-2.
39. Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010;35:105-11.
40. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010;181:270-8.
41. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-28.
42. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial. Lancet. 2002;360:895-900.
43. Jackson RM, Glassberg MK, Ramos CF, Bejarano PA, Butrous G, Gomez-Marin O. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung 2010;188:115-23.
44. Barnett CF, Bonura EJ, Nathan SD, Ahmad S, Shlobin OA, Osei K, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009;135:1455-61.
45. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-8.
46. Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010;79:377-82.
47. Tissieres P, Nicod L, Barazzone-Argiroffo C, Rimensberger PC, Beghetti M. Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension. Ann Thorac Surg 2004;78:e48-50.
48. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the pulmonary scientific council of the international society for heart and lung transplantation. J Heart Lung Transplant 2006;25:745-55.
49. Rothman A, Sklansky MS, Lucas VW, Kashani IA, Shaughnessy RD, Channick RN, et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999;84:682-6.
50. Davis SQ, Garrity ER Jr. Organ allocation in lung transplant. Chest 2007;132:1646-51.
51. Chen H, Shiboski SC, Golden JA, Gould MK, Hays SR, Hoopes CW, et al. Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension. Am J Respir Crit Care Med 2009;180:468-74.
52. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010;122:164-72.
53. Chan KM. Idiopathic pulmonary arterial hypertension and equity of donor lung allocation in the era of the lung allocation score: Are we there yet? Am J Respir Crit Care Med 2009;180:385-7.
54. Gammie JS, Keenan RJ, Pham SM, McGrath MF, Hattler BG, Khoshbin E, et al. Single-versus double-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1998;115:397-402.
55. Bando K, Armitage JM, Paradis IL, Keenan RJ, Hardesty RL, Konishi H, et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1994;108:1056-65.
56. Bando K, Keenan RJ, Paradis IL, Konishi H, Komatsu K, Hardesty RL, et al. Impact of pulmonary hypertension on outcome after single-lung transplantation. Ann Thorac Surg 1994;58:1336-42.
57. Conte JV, Borja MJ, Patel CB, Yang SC, Jhaveri RM, Orens JB. Lung transplantation for primary and secondary pulmonary hypertension. Ann Thorac Surg 2001;72:1673-79; discussion 1679-80.
58. Levine SM, Gibbons WJ, Bryan CL, Walling AD, Brown RW, Bailey SR, et al. Single lung transplantation for primary pulmonary hypertension. Chest 1990;98:1107-15.
59. Girard C, Mornex JF, Gamondes JP, Griffith N, Clerc J. Single lung transplantation for primary pulmonary hypertension without cardiopulmonary bypass. Chest 1992;102:967-8.
60. Pasque MK, Trulock EP, Cooper JD, Triantafillou AN, Huddleston CB, Rosenbloom M, et al. Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients. Circulation 1995;92:2252-8.
61. Katz WE, Gasior TA, Quinlan JJ, Lazar JM, Firestone L, Griffith BP, et al. Immediate effects of lung transplantation on right ventricular morphology and function in patients with variable degrees of pulmonary hypertension. J Am Coll Cardiol 1996;27:384-91.
62. Mendeloff EN, Meyers BF, Sundt TM, Guthrie TJ, Sweet SC, de la Morena M, et al. Lung transplantation for pulmonary vascular disease. Ann Thorac Surg 2002;73:209-17.
63. Thabut G, Vinatier I, Stern JB, Leseche G, Loirat P, Fournier M, et al. Primary graft failure following lung transplantation: Predictive factors of mortality. Chest 2002;121:1876-82.
64. Whitson BA, Nath DS, Johnson AC, Walker AR, Prekker ME, Radosevich DM, et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2006;131:73-80.
65. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT working group on primary lung graft dysfunction part II: Definition. A consensus statement of the international society for heart and lung transplantation. J Heart Lung Transplant 2005;24:1454-9.
66. Lee J, Kuntz C, Kawut S, Hadjiliadis D, Ahya V, Wille K, et al. 21: Clinical risk factors for the development of primary graft dysfunction. J Heart Lung Transplant 2008;27:S67-8.
67. Christie JD, Kotloff RM, Pochettino A, Arcasoy SM, Rosengard BR, Landis JR, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003;124:1232-41.
68. Kuntz CL, Hadjiliadis D, Ahya VN, Kotloff RM, Pochettino A, Lewis J, et al. Risk factors for early primary graft dysfunction after lung transplantation: A registry study. Clin Transplant 2009;23:819-30.
69. Fang A, Studer S, Kawut SM, Ahya VN, Lee J, Wille K, et al. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest 2011;139:782-7.
70. Thabut G, Christie JD, Kremers WK, Fournier M, Halpern SD. Survival differences following lung transplantation among us transplant centers. JAMA 2010;304:53-60.
71. Toyoda Y, Thacker J, Santos R, Nguyen D, Bhama J, Bermudez C, et al. Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. Ann Thorac Surg 2008;86:1116-22.
72. Fadel E, Mercier O, Mussot S, Leroy-Ladurie F, Cerrina J, Chapelier A, et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: A comparative retrospective study of 219 patients. Eur J Cardiothorac Surg 2010;38:277-84.
73. Gross CR, Savik K, Bolman RM 3rd, Hertz MI. Long-term health status and quality of life outcomes of lung transplant recipients. Chest 1995;108:1587-93.